Patient demographics and disease characteristics
| . | N = 48 . |
|---|---|
| Age, median (range), y | 64 (35-83) |
| Distribution, no. (%) | |
| <65 | 26 (54) |
| 65-74 | 16 (37) |
| ≥75 | 6 (13) |
| Sex, no. (%) | |
| Male | 31 (65) |
| Female | 17 (35) |
| Race, no. (%) | |
| White | 26 (54) |
| African American | 18 (38) |
| Other (Hispanic, Asian) | 4 (8) |
| Performance status (ECOG), no. (%) | |
| 0-1 | 46 (96) |
| 2 | 2 (4) |
| Isotype, no. (%) | |
| IgG | 29 (60) |
| IgA, IgD | 7 (15), 1 (2) |
| Light chain | 11 (23) |
| Urine, serum only | 7 (15); 4 (8) |
| LDH, median (range), units/L | 500 (150-4834) |
| >Normal, no. (%) | 4 (8) |
| Creatinine, median (range), mg/dL | 1 (0.8-1.8) |
| % BM plasmacytosis, median (range) | 20 (15-100) |
| Cytogenetics/FISH, no. (%) | |
| Standard risk (normal, hyperdiploid, t(11:14)) | 18 (10, 6, 2) (38) |
| High risk (del 17p, t(14:16), t(14:20), t(4:14), 1q+) | 30 (6, 4, 2, 5, 13) (62) |
| Median time from diagnosis to study (range), y | 4 (1.2-26) |
| Median lines of prior therapy (range) | 3 (2-5) |
| Distribution, no. (%) | |
| 2-3 | 17-18 (35-38) |
| >3 | 13 (27) |
| Prior therapy, no. (%) | |
| ASCT | 31 (72) |
| Proteosome inhibitors | 48 (100) |
| Bortezomib | 48 (100) |
| Carfilzomib | 24 (50) |
| IMiDs | 48 (100) |
| Lenalidomide | 48 (100) |
| Refractory, no. (%) | |
| Proteosome inhibitors | 38 (79) |
| Lenalidomide | 43 (90) |
| Double refractory to IMiDs and proteosome inhibitors | 35 (73) |
| . | N = 48 . |
|---|---|
| Age, median (range), y | 64 (35-83) |
| Distribution, no. (%) | |
| <65 | 26 (54) |
| 65-74 | 16 (37) |
| ≥75 | 6 (13) |
| Sex, no. (%) | |
| Male | 31 (65) |
| Female | 17 (35) |
| Race, no. (%) | |
| White | 26 (54) |
| African American | 18 (38) |
| Other (Hispanic, Asian) | 4 (8) |
| Performance status (ECOG), no. (%) | |
| 0-1 | 46 (96) |
| 2 | 2 (4) |
| Isotype, no. (%) | |
| IgG | 29 (60) |
| IgA, IgD | 7 (15), 1 (2) |
| Light chain | 11 (23) |
| Urine, serum only | 7 (15); 4 (8) |
| LDH, median (range), units/L | 500 (150-4834) |
| >Normal, no. (%) | 4 (8) |
| Creatinine, median (range), mg/dL | 1 (0.8-1.8) |
| % BM plasmacytosis, median (range) | 20 (15-100) |
| Cytogenetics/FISH, no. (%) | |
| Standard risk (normal, hyperdiploid, t(11:14)) | 18 (10, 6, 2) (38) |
| High risk (del 17p, t(14:16), t(14:20), t(4:14), 1q+) | 30 (6, 4, 2, 5, 13) (62) |
| Median time from diagnosis to study (range), y | 4 (1.2-26) |
| Median lines of prior therapy (range) | 3 (2-5) |
| Distribution, no. (%) | |
| 2-3 | 17-18 (35-38) |
| >3 | 13 (27) |
| Prior therapy, no. (%) | |
| ASCT | 31 (72) |
| Proteosome inhibitors | 48 (100) |
| Bortezomib | 48 (100) |
| Carfilzomib | 24 (50) |
| IMiDs | 48 (100) |
| Lenalidomide | 48 (100) |
| Refractory, no. (%) | |
| Proteosome inhibitors | 38 (79) |
| Lenalidomide | 43 (90) |
| Double refractory to IMiDs and proteosome inhibitors | 35 (73) |
ASCT, autologous stem cell transplant; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.